Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α. A Pilot Proof of Principle Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Plasma TNF-alpha concentration following LPS administration
研究概览
简要总结
Oxygen is a widely available gas that is cheap, easy to get and extensively used in medicine. From animal studies it has become apparent that increasing or lowering the degree of oxygen in the blood, the inflammatory response can be altered. We will investigate of this is also true in humans by increasing, lowering or keeping oxygen levels normal while giving healthy subjects a short inflammatory stimulus.
详细描述
The primary objective of the study is to determine the effects of hyperoxia and hypoxia compared to normoxia in the human endotoxemia model on the innate immune reponse in healthy volunteers.
A parallel, randomized study in healthy male volunteers. The subjects will be randomized to hypoxia, hyperoxia, or normoxia, and will all undergo experimental human endotoxemia (administration of 2 ng/kg LPS iv).
In the hypoxia group: the subjects will breathe an individualized mix of nitrogen and room air for 3.5 hours using an air-tight respiratory helmet. The gas mixture will be adjusted to achieve a saturation of 80-85%. In the hyperoxia group, subjects will breathe 100% oxygen for 3.5 hours using the same respiratory helmet. In the normoxia group, subjects will breathe room air (21% oxygen, 79% nitrogen) also wearing the respiratory helmet. 1 hour after oxygen status adjustment (t=0), all subject will be administered an intravenous bolus (2ng/kg) of LPS derived from E coli O:113. 2.5 hours after LPS administration, the helmets will be removed and all subjects will breathe ambient room air.
The primary study endpoint is the difference in plasma cytokines between the hypoxia and normoxia group, and between the hyperoxia and normoxia group. Secondary objectives include HIF-1α protein and mRNA, aHIF mRNA expression in circulating leukocytes, measures of ROS, leukocyte phagocytosis, and cytokine production by leukocytes stimulated ex vivo with various inflammatory stimuli, and measurement of basic hemodynamic and ventilatory parameters and temperature.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent to participate in this trial
- •Male subjects aged 18 to 35 years inclusive
- •Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters
排除标准
- •Use of any medication(including herbal remedies and vitamin/mineral supplements) or recreational drugs within 7 days prior to profiling day
- •Use of caffeine, or alcohol or within 1 day prior to profiling day
- •Previous participation in a trial where LPS was administered
- •Surgery or trauma with significant blood loss or blood donation within 3 months prior to profiling day
- •Participation in another clinical trial within 3 months prior to profiling day.
- •History, signs or symptoms of cardiovascular disease
- •An implant that in the opinion of the investigator may make invasive procedures risky for the subject due to the increased risks associated with a possible infection.
- •Subject has an implanted active cardiac device (ICD, IPG and/or CRT) Implanted active neurostimulation device
- •Subject has internal jugular vein that cannot be accessed
- •History of vaso-vagal collapse or of orthostatic hypotension
- •History of atrial or ventricular arrhythmia
- •Resting pulse rate ≤45 or ≥100 beats / min
- •Hypertension (RR systolic >160 or RR diastolic >90)
- •Hypotension (RR systolic <100 or RR diastolic <50)
- •Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complex bundle branch block
- •Subject is diagnosed with epilepsy or history of seizures
- •Renal impairment: plasma creatinine >120 μmol/L
- •Liver function abnormality: alkaline phosphatase>230 U/L and/or ALT>90 U/L
- •Coagulation abnormalities: APTT or PT > 1.5 times the reference range
- •History of asthma
- •Immuno-deficiency CRP > 20 mg/L, WBC > 12x109/L, or clinically significant acute illness, including infections, within 2 weeks before profiling day
- •Known or suspected of not being able to comply with the trial protocol - Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.
研究组 & 干预措施
Hypoxia
Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
干预措施: Lipopolysaccharide (Drug)
Hyperoxia
Subjects will be breathing 100% of oxygen
干预措施: Lipopolysaccharide (Drug)
Normoxia
Subjects wil be breathing room air (21%)
干预措施: Lipopolysaccharide (Drug)
结局指标
主要结局
Plasma TNF-alpha concentration following LPS administration
时间窗: 1 day
Plasma TNF-α concentration after LPS administration (Area Under Curve); comparison of subjects treated with hypoxia compared to normoxia and hyperoxia compared to hypoxia
次要结局
- Hypoxia Inducible Factor 1 alpha in circulating leukocytes(1 day)
- Hypoxia Inducible Factor mRNA and anti Hypoxia Inducible Factor mRNA in circulating leukocytes(24 hours)
- Reactive Oxygen Species in circulating leukocytes(1 day)
- Phagocytic function of circulating leukocytes(1 day)
- cytokine production after ex vivo stimulation of leukocytes(1 day)
- circulating cytokines (including but not limited to IL-6, IL-10, IL-1RA)(1 day)
- Hemodynamic parameters(1 day)
- ventilatory response(1 day)
- oxygen saturation and arterial blood gas(1)
- subjective symptom scores(1 day)
- high sensitive troponine(1 day)
- iFABP(1 day)
- brain specific proteins(1 day)
- endocan(1 day)
- downstream targets of HIF(1 day)
- adenosine metabolism(1 day)
- alkaline phosphatase(1 day)
- cognitive function(1 day)
- Hepcidin and iron parameters(1 day)
- catecholamines and cortisol(1 day)
- Neutrophilic function(1 day)
- body temperature(1 day)
- heart rate variability(1 day)
- kidney injury markers in plasma and urine(2 days)
- microbiome in feces(-1 day untill 1 week)
- markers of immunoparalysis(1 day)
- measures of coagulation and plateletfunction(1 day)
- meausures of coagulation and fibrinolysis(1 day)